Late Breaking Abstract - International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs
C. Caruso (Rome, Italy), G. Canonica (Milan, Italy), M. Patel (Wishaw, United Kingdom), A. Smith (Wishaw, United Kingdom), M. Liu (Baltimore, United States), R. Alfonso-Cristancho (Collegeville, United States), R. Price (Stevenage, United Kingdom), R. Jakes (Brentford, United Kingdom), L. Demetriou (Stevenage, United Kingdom), A. Valero (Barcelona, Spain), C. Pilette (Brussels, Belgium), P. Howarth (Brentford, United Kingdom)
Source: International Congress 2022 – Late-breaking abstracts in airway disease
Session: Late-breaking abstracts in airway disease
Session type: Thematic Poster
Number: 4186
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Caruso (Rome, Italy), G. Canonica (Milan, Italy), M. Patel (Wishaw, United Kingdom), A. Smith (Wishaw, United Kingdom), M. Liu (Baltimore, United States), R. Alfonso-Cristancho (Collegeville, United States), R. Price (Stevenage, United Kingdom), R. Jakes (Brentford, United Kingdom), L. Demetriou (Stevenage, United Kingdom), A. Valero (Barcelona, Spain), C. Pilette (Brussels, Belgium), P. Howarth (Brentford, United Kingdom). Late Breaking Abstract - International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs. 4186
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|